Treatment Resistant Depression

We currently offer two studies involving depression, more info below

Cariprazine as an Adjunctive Treatment to Antidepressant Therapy

Michigan Clinical Research Institute is currently enrolling for a clinical research study for adults ages 18-65 who have been diagnosed with Major Depressive Disorder (MDD).

An individual may qualify for the study if they:
– Are 18 to 65 years of age
– Have been diagnosed with Major Depressive Disorder (MDD)
– Have had an inadequate response to 1-3 antidepressants
– Meet additional study criteria

Reimbursement for reasonable, out-of-pocket expenses for travel and accommodations may be available to qualified individuals.

View more information at:

LivaNova RECOVER Study

One out of every three patients who have tried several antidepressant treatments still have symptoms of depression. The RECOVER study is a new research study for people with difficult-to-treat depression.

VNS (Vagus Nerve Stimulation) Therapy is a well-studied treatment that is already approved by the FDA for people with treatment-resistant depression. Despite this, Medicare and other insurers do not routinely cover it

The RECOVER study was designed in partnership with many of the nation’s top experts in treatment resistant depression, and approved by Medicare, to provide additional evidence of the benefit of VNS Therapy. If the results confirm previous studies, Medicare and other insurers may start to cover it.

To join the RECOVER study, you must be 18 years or older and:
– Currently depressed
– Have depression, or bipolar depression, that has lasted for at least two years or recurred several times
-Have tried at least four types of antidepressant treatments and not found them helpful

View more information at: